High grade gliomas represent one of the most aggressive and treatment-resistant types of human cancer, with only 1–2 years median survival rate for patients with grade IV glioma. The treatment of glioblastoma is a considerable therapeutic challenge; combination therapy targeting multiple pathways is becoming a fast growing area of research. This review offers an up-to-date perspective of the literature about current molecular therapy targets in high grade glioma, that include angiogenic signals, tyrosine kinase receptors, nodal signaling proteins and cancer stem cells related approaches. Simultaneous identification of proteomic signatures could provide biomarker panels for diagnostic and personalized treatment of different subsets of glioblastoma. Personalized medicine is starting to gain importance in clinical care, already having recorded a series of successes in several types of cancer; nonetheless, in brain tumors it is still at an early stage.

中文翻译：

---

高级别胶质瘤的抗癌治疗

高级别神经胶质瘤是最具侵袭性和抗治疗性的人类癌症之一，IV 级神经胶质瘤患者的中位生存率只有 1-2 年。胶质母细胞瘤的治疗是一个相当大的治疗挑战。针对多种途径的联合治疗正在成为一个快速增长的研究领域。本综述提供了关于当前高级别胶质瘤分子治疗靶点的文献的最新观点，包括血管生成信号、酪氨酸激酶受体、节点信号蛋白和癌症干细胞相关方法。同时识别蛋白质组学特征可以为胶质母细胞瘤不同亚群的诊断和个性化治疗提供生物标志物面板。个性化医疗开始在临床护理中变得越来越重要，已经在几种类型的癌症中取得了一系列成功；尽管如此，在脑肿瘤中它仍处于早期阶段。